Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-09-23
DOI
10.1093/ibd/izaa236
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
- (2019) Subrata Ghosh et al. DRUG SAFETY
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
- (2018) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Malignancies in Inflammatory Bowel Disease
- (2018) Sylvie Scharl et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry
- (2017) David Fiorentino et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology
- (2014) Geoffrey C. Nguyen et al. GASTROENTEROLOGY
- Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment
- (2014) Alfredo Papa WORLD JOURNAL OF GASTROENTEROLOGY
- Inflammatory bowel disease and thromboembolism
- (2014) Petros Zezos WORLD JOURNAL OF GASTROENTEROLOGY
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
- (2012) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study
- (2010) Matthew J Grainge et al. LANCET
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy
- (2008) Eugeni Domènech et al. INFLAMMATORY BOWEL DISEASES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started